Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

Innovation Pharmaceuticals Inc. (OTCQB:IPIX) reported top-line data from 46 patients receiving chemoradiation for head and neck cancer in the modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15 mL Brilacidin-OM for seven weeks met the primary endpoint of reducing the incidence of severe oral mucositis (OM) vs. placebo (42.9% vs. 60%). Brilacidin-OM was generally well tolerated.

Secondary endpoints in the double-blind, U.S. trial include duration of severe OM and time to onset of severe OM...